Clinical Trials Directory

We are doing this study to look at blood, tumor, and lymph node tissue from people with melanoma so we can improve diagnostic methods and therapies for people with melanoma.

We are doing this study to find out if the study drug, pembrolizumab, is a safe and effective treatment for metastatic castrate-resistant prostate cancer when it is given in different combinations with other drugs. Pembrolizumab may work by increasing your immune system's response against a tumor.

We are doing this study to find the most effective, safe dose of an experimental drug called V940 (the study drug) when it is given with pembrolizumab to people who have had surgery to remove renal cell carcinoma. We want to know how well this combination works compared to taking pembrolizumab on its own.

We are doing this study to find the most effective, safe dose of an experimental drug called bomedemstat (the study drug) for people with essential thrombocythemia who are unable to take hydroxyurea or do not get a benefit from it.

We are doing this study to find out if an experimental drug called MK-2870 (the study drug) is an option for patients with endometrial cancer. We want to know how well it works compared to standard chemotherapy.

We are doing this study to find the most effective, safe dose of an experimental drug called bomedemstat or hydroxyurea in people with essential thrombocythemia (ET). We also want to know which of these options works best for most people.

We are doing this study to find out if giving patients a drug called atezolizumab before and after surgery for recurrent glioblastoma can improve how their cancer responds.

We are doing this study to see how tucatinib, trastuzumab, and mFOLFOX6 work to treat cancer of your colon or rectum that is HER2-positive with mFOLFOX6 alone or combined with bevacizumab.